Seqens Seqens

X

Find Drugs in Development News & Deals for NCGC00024433-05

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
93
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

USP

JP

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • TABLET;ORAL - 100MG
  • TABLET;ORAL - 10MG
  • TABLET;ORAL - 150MG
  • TABLET;ORAL - 25MG
  • TABLET;ORAL - 50MG
  • TABLET;ORAL - 75MG

Details:

ATX01 (amitriptyline hydrochloride) topical which is investigated in Phase 2 for pain of Erythromelalgia, a rare neurological and vascular disease characterized by painful extremities for which there is no available treatment. The trial is due to read out in H1 2024.


Lead Product(s): Amitriptyline Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Product Name: ATX01

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The net proceedings will be used to demonstrate the clinical efficacy of ATX01 (amitriptyline hydrochloride) in Phase 2 in chemotherapy-induced peripheral neuropathy and erythromelalgia.


Lead Product(s): Amitriptyline Hydrochloride

Therapeutic Area: Product Name: ATX01

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Relyens Innovation Santé

Deal Size: $21.2 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments.


Lead Product(s): Chlordiazepoxide,Amitriptyline Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Limbitrol

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: MedQuímica Indústria Farmacêutica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 28, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The ANDA approval is for Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the USFDA to market a generic version of ELAVIL (Amitriptyline Hydrochloride) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg of AstraZeneca Pharmaceuticals LP.


Lead Product(s): Amitriptyline Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY